ABBOTT LABORATORIES
ABTNYSETrading Snapshot
- Day Range
- $98.90 β $101.46
- 52-Week Range
- $81.97 β $135.45
- Volume
- $8.84B
- Avg Volume
- $6.30B
- Shares Outstanding
- 1.73B
- Next Earnings
- Nov 3, 2026
Fundamentals Snapshot
- Annual Revenue
- $44.33B
- Last Q Revenue
- $12.59B
- P/E Ratio
- 32.6
- P/S Ratio
- 3.8x
- EPS (TTM)
- $3.11
- Dividend Yield
- 2.45%
- Dilution (1yr)
- +0.1%
Why Investors Own ABT
- βHigh-growth profile β revenue up +1.5% YoY with expanding US Equity exposure.
- βHealthy economics β 67% gross margin and 19% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ABBOTT LABORATORIES
ABTAbout ABBOTT LABORATORIES
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
ABBOTT LABORATORIES tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift ABT price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
ABBOTT LABORATORIES announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.